In 2023, China had an actual number of 17.85 thousand confirmed cases of Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB). The forecasts from 2024 to 2028 show a steady increase each year, with values ranging from 18.62 thousand in 2024 to 21.74 thousand in 2028. The year-on-year percentage variation indicates an upward trend, with notable increments between 2024 and 2025 (4.30%), and between 2025 and 2026 (4.12%). The five-year compound annual growth rate (CAGR) forecasts an average annual increase of approximately 4.04%.
Future trends to watch include the potential impact of enhanced public health measures and innovation in treatment methods, which could moderate the rise in RR-/MDR-TB cases. Additionally, monitoring the influence of policy changes and healthcare access improvements will be crucial in understanding and potentially curbing the growth of these resistant TB strains.
